Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

PRGO vs TEVA vs AMRX vs MCK vs CAH

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.61B
5Y Perf.-78.6%
TEVA
Teva Pharmaceutical Industries Limited

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IL
Market Cap$41.93B
5Y Perf.+187.4%
AMRX
Amneal Pharmaceuticals, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$4.31B
5Y Perf.+181.7%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+374.1%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.59B
5Y Perf.+238.7%

PRGO vs TEVA vs AMRX vs MCK vs CAH — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PRGO logoPRGO
TEVA logoTEVA
AMRX logoAMRX
MCK logoMCK
CAH logoCAH
IndustryDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & GenericMedical - DistributionMedical - Distribution
Market Cap$1.61B$41.93B$4.31B$92.15B$43.59B
Revenue (TTM)$4.18B$17.35B$3.02B$403.43B$250.55B
Net Income (TTM)$-1.82B$1.56B$72M$4.76B$1.56B
Gross Margin34.2%52.1%36.9%3.6%3.7%
Operating Margin-4.1%13.2%-0.2%1.5%0.9%
Forward P/E5.6x14.5x13.8x19.3x17.9x
Total Debt$3.97B$17.38B$124M$7.39B$9.35B
Cash & Equiv.$532M$3.56B$282M$5.69B$3.87B

PRGO vs TEVA vs AMRX vs MCK vs CAHLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PRGO
TEVA
AMRX
MCK
CAH
StockMay 20May 26Return
Perrigo Company plc (PRGO)10021.4-78.6%
Teva Pharmaceutical… (TEVA)100287.4+187.4%
Amneal Pharmaceutic… (AMRX)100281.7+181.7%
McKesson Corporation (MCK)100474.1+374.1%
Cardinal Health, In… (CAH)100338.7+238.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: PRGO vs TEVA vs AMRX vs MCK vs CAH

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PRGO and TEVA are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Teva Pharmaceutical Industries Limited is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. MCK and CAH also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
PRGO
Perrigo Company plc
The Value Play

PRGO has the current edge in this matchup, primarily because of its strength in value and dividends.

  • Lower P/E (5.6x vs 17.9x)
  • 9.8% yield, 10-year raise streak, vs CAH's 1.1%, (2 stocks pay no dividend)
Best for: value and dividends
TEVA
Teva Pharmaceutical Industries Limited
The Quality Compounder

TEVA is the #2 pick in this set and the best alternative if quality and momentum is your priority.

  • 9.0% margin vs PRGO's -43.5%
  • +104.6% vs PRGO's -51.2%
Best for: quality and momentum
AMRX
Amneal Pharmaceuticals, Inc.
The Growth Play

AMRX is the clearest fit if your priority is growth exposure and sleep-well-at-night.

  • Rev growth 8.0%, EPS growth 157.9%, 3Y rev CAGR 10.9%
  • Lower volatility, beta 1.17, Low D/E 12.8%, current ratio 2.17x
Best for: growth exposure and sleep-well-at-night
MCK
McKesson Corporation
The Long-Run Compounder

MCK ranks third and is worth considering specifically for long-term compounding.

  • 348.1% 10Y total return vs CAH's 160.8%
  • 16.2% revenue growth vs PRGO's -2.8%
  • 5.7% ROA vs PRGO's -19.8%, ROIC 5.4% vs 3.7%
Best for: long-term compounding
CAH
Cardinal Health, Inc.
The Income Pick

CAH is the clearest fit if your priority is income & stability and defensive.

  • Dividend streak 20 yrs, beta 0.03, yield 1.1%
  • Beta 0.03, yield 1.1%, current ratio 0.94x
  • Beta 0.03 vs PRGO's 1.18
Best for: income & stability and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthMCK logoMCK16.2% revenue growth vs PRGO's -2.8%
ValuePRGO logoPRGOLower P/E (5.6x vs 17.9x)
Quality / MarginsTEVA logoTEVA9.0% margin vs PRGO's -43.5%
Stability / SafetyCAH logoCAHBeta 0.03 vs PRGO's 1.18
DividendsPRGO logoPRGO9.8% yield, 10-year raise streak, vs CAH's 1.1%, (2 stocks pay no dividend)
Momentum (1Y)TEVA logoTEVA+104.6% vs PRGO's -51.2%
Efficiency (ROA)MCK logoMCK5.7% ROA vs PRGO's -19.8%, ROIC 5.4% vs 3.7%

PRGO vs TEVA vs AMRX vs MCK vs CAH — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
TEVATeva Pharmaceutical Industries Limited
FY 2025
Product
84.6%$14.6B
Distribution Service
9.0%$1.6B
License
3.9%$678M
Product and Service, Other
2.5%$423M
AMRXAmneal Pharmaceuticals, Inc.
FY 2024
Specialty Segment
100.0%$446M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B

PRGO vs TEVA vs AMRX vs MCK vs CAH — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPRGOLAGGINGCAH

Income & Cash Flow (Last 12 Months)

TEVA leads this category, winning 4 of 6 comparable metrics.

MCK is the larger business by revenue, generating $403.4B annually — 133.6x AMRX's $3.0B. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, AMRX holds the edge at +11.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…AMRX logoAMRXAmneal Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
RevenueTrailing 12 months$4.2B$17.3B$3.0B$403.4B$250.5B
EBITDAEarnings before interest/tax$58M$3.3B$169M$6.8B$3.2B
Net IncomeAfter-tax profit-$1.8B$1.6B$72M$4.8B$1.6B
Free Cash FlowCash after capex$108M$1.2B$150M$6.0B$4.4B
Gross MarginGross profit ÷ Revenue+34.2%+52.1%+36.9%+3.6%+3.7%
Operating MarginEBIT ÷ Revenue-4.1%+13.2%-0.2%+1.5%+0.9%
Net MarginNet income ÷ Revenue-43.5%+9.0%+2.4%+1.2%+0.6%
FCF MarginFCF ÷ Revenue+2.6%+6.8%+5.0%+1.5%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year-7.2%+2.3%+11.5%+6.0%+11.0%
EPS Growth (YoY)Latest quarter vs prior year-56.4%+72.2%+2.1%+37.0%-19.5%
TEVA leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 5 of 6 comparable metrics.

At 28.7x trailing earnings, CAH trades at a 54% valuation discount to AMRX's 62.4x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than MCK's 18.7x.

MetricPRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…AMRX logoAMRXAmneal Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Market CapShares × price$1.6B$41.9B$4.3B$92.1B$43.6B
Enterprise ValueMkt cap + debt − cash$5.1B$55.8B$4.2B$93.8B$49.1B
Trailing P/EPrice ÷ TTM EPS-1.14x30.01x62.36x29.25x28.72x
Forward P/EPrice ÷ next-FY EPS est.5.56x14.55x13.81x19.28x17.94x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple7.42x17.65x18.74x16.01x
Price / SalesMarket cap ÷ Revenue0.38x2.43x1.43x0.26x0.20x
Price / BookPrice ÷ Book value/share0.55x5.34x4.62x
Price / FCFMarket cap ÷ FCF11.12x36.52x15.98x17.63x23.56x
PRGO leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

Evenly matched — AMRX and MCK each lead in 4 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-51 for PRGO. AMRX carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs PRGO's 4/9, reflecting strong financial health.

MetricPRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…AMRX logoAMRXAmneal Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
ROE (TTM)Return on equity-50.7%+20.7%+7.5%+3.0%
ROA (TTM)Return on assets-19.8%+3.9%+2.0%+5.7%+2.8%
ROICReturn on invested capital+3.7%+7.7%-0.2%+5.4%+33.8%
ROCEReturn on capital employed+4.3%+8.0%-0.2%+30.5%+19.2%
Piotroski ScoreFundamental quality 0–948866
Debt / EquityFinancial leverage1.35x2.20x0.13x
Net DebtTotal debt minus cash$3.4B$13.8B-$158M$1.7B$5.5B
Cash & Equiv.Liquid assets$532M$3.6B$282M$5.7B$3.9B
Total DebtShort + long-term debt$4.0B$17.4B$124M$7.4B$9.3B
Interest CoverageEBIT ÷ Interest expense-7.20x2.51x2.09x33.79x6.38x
Evenly matched — AMRX and MCK each lead in 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — TEVA and AMRX and MCK each lead in 2 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, TEVA leads with a +104.6% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors AMRX at 89.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.

MetricPRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…AMRX logoAMRXAmneal Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
YTD ReturnYear-to-date-13.5%+16.3%+8.4%-8.5%-9.5%
1-Year ReturnPast 12 months-51.2%+104.6%+90.0%+4.6%+22.0%
3-Year ReturnCumulative with dividends-58.1%+297.5%+579.2%+106.4%+127.3%
5-Year ReturnCumulative with dividends-60.1%+246.2%+163.8%+286.9%+235.7%
10-Year ReturnCumulative with dividends-77.7%-28.3%-54.9%+348.1%+160.8%
CAGR (3Y)Annualised 3-year return-25.2%+58.4%+89.4%+27.3%+31.5%
Evenly matched — TEVA and AMRX and MCK each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — TEVA and CAH each lead in 1 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…AMRX logoAMRXAmneal Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Beta (5Y)Sensitivity to S&P 5001.18x1.13x1.17x0.04x0.03x
52-Week HighHighest price in past year$28.44$37.35$15.20$999.00$233.60
52-Week LowLowest price in past year$9.23$14.99$7.02$637.00$137.75
% of 52W HighCurrent price vs 52-week peak+41.2%+96.4%+90.3%+75.3%+79.3%
RSI (14)Momentum oscillator 0–10060.973.562.716.233.2
Avg Volume (50D)Average daily shares traded3.4M6.6M1.7M757K1.7M
Evenly matched — TEVA and CAH each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — PRGO and CAH each lead in 1 of 2 comparable metrics.

Analyst consensus: PRGO as "Hold", TEVA as "Buy", AMRX as "Buy", MCK as "Buy", CAH as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 8.3% for TEVA (target: $39). For income investors, PRGO offers the higher dividend yield at 9.81% vs MCK's 0.36%.

MetricPRGO logoPRGOPerrigo Company p…TEVA logoTEVATeva Pharmaceutic…AMRX logoAMRXAmneal Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …
Analyst RatingConsensus buy/hold/sellHoldBuyBuyBuyBuy
Price TargetConsensus 12-month target$20.00$39.00$17.00$1006.50$249.67
# AnalystsCovering analysts3646163133
Dividend YieldAnnual dividend ÷ price+9.8%+0.4%+1.1%
Dividend StreakConsecutive years of raises10101720
Dividend / ShareAnnual DPS$1.15$2.69$2.04
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+3.4%+1.8%
Evenly matched — PRGO and CAH each lead in 1 of 2 comparable metrics.
Key Takeaway

TEVA leads in 1 of 6 categories (Income & Cash Flow). PRGO leads in 1 (Valuation Metrics). 4 tied.

Best OverallPerrigo Company plc (PRGO)Leads 1 of 6 categories
Loading custom metrics...

PRGO vs TEVA vs AMRX vs MCK vs CAH: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PRGO or TEVA or AMRX or MCK or CAH a better buy right now?

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 9x forward), making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PRGO or TEVA or AMRX or MCK or CAH?

On trailing P/E, Cardinal Health, Inc.

(CAH) is the cheapest at 28. 7x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — PRGO or TEVA or AMRX or MCK or CAH?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: MCK returned +348. 1% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PRGO or TEVA or AMRX or MCK or CAH?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 3385% more volatile than CAH relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — PRGO or TEVA or AMRX or MCK or CAH?

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PRGO or TEVA or AMRX or MCK or CAH?

Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.

2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PRGO or TEVA or AMRX or MCK or CAH more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

6x forward P/E versus 19. 3x for McKesson Corporation — 13. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

08

Which pays a better dividend — PRGO or TEVA or AMRX or MCK or CAH?

In this comparison, PRGO (9.

8% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. TEVA, AMRX do not pay a meaningful dividend and should not be held primarily for income.

09

Is PRGO or TEVA or AMRX or MCK or CAH better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Both have compounded well over 10 years (CAH: +160. 8%, AMRX: -54. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PRGO and TEVA and AMRX and MCK and CAH?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PRGO is a small-cap income-oriented stock; TEVA is a mid-cap quality compounder stock; AMRX is a small-cap quality compounder stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock. PRGO, CAH pay a dividend while TEVA, AMRX, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.9%
Run This Screen
Stocks Like

TEVA

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

AMRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Gross Margin > 22%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PRGO and TEVA and AMRX and MCK and CAH on the metrics below

Revenue Growth>
%
(PRGO: -7.2% · TEVA: 2.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.